RPG Life Sciences Limited has accepted the cessation of Samir Rane as Vice President, Sales & Marketing - Main Division, with effect from the close of business hours on July 31, 2026. The departure is consequential to his retirement upon attaining the age of superannuation, marking a transition in the company's senior management structure for its main division.

The disclosure was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the details to the National Stock Exchange of India Limited and BSE Limited, referencing SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Rajesh Shirambekar, Head – Legal & Company Secretary, signed the communication on July 31, 2026.

Cessation Details

The filing outlines the specific particulars regarding the change in senior management personnel:

What This Means for Leadership

Samir Rane’s role as Vice President, Sales & Marketing - Main Division, was part of the Senior Management Personnel framework defined under SEBI listing regulations. His retirement represents a standard succession event driven by age limits rather than voluntary resignation or removal. The company has not disclosed an immediate replacement in this filing, indicating that internal restructuring or external hiring for the Sales & Marketing - Main Division role may follow in subsequent announcements.

RPG Life Sciences has executed a Business Transfer Agreement to slump sale its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), for ₹33.55 crore. The transaction, approved by the Board on July 29, 2026, aims to create a focused API entity with dedicated capital, while the parent company concentrates on its formulations business. This strategic restructuring positions the API segment to attract external investment and pursue aggressive growth in a structurally realigning global supply chain.

The sale consideration of ₹33.55 crore is subject to adjustments based on actual assets and liabilities at closing, expected by September 30, 2026. Concurrently, RPGAP has entered into an investment agreement with India Life Sciences Fund IV Domestic (ILSF) and Vistaject Fund (VJF). Funds managed by these entities will make an initial investment of up to ₹243.33 crore in RPGAP for a stake of about 40% on a fully diluted basis. The parties have committed to infusing an aggregate amount of up to ₹700 crore in tranches to fund organic and inorganic growth, including manufacturing expansion and product portfolio enhancement.

Financial Impact and Rationale

The API business contributed ₹95.06 crore to revenue in FY26, representing 13.54% of consolidated turnover. Its net worth stood at ₹70.92 crore as of March 31, 2026. Management stated that the spin-off allows sharper focus on API growth within the subsidiary structure. Ashok Nair, Managing Director of RPG Life Sciences, noted that the partnership brings specialized investing experience to complement the company’s execution track record.

Investment and Acquisition Strategy

RPGAP has also executed a Share Purchase Agreement to acquire 100% of Actis Generics Private Limited (Actis), an API manufacturer based in Visakhapatnam. The acquisition cost is ₹80 crore, subject to working capital adjustments, with completion targeted by November 15, 2026. Actis reported a turnover of ₹48.24 crore in FY25. Dr. Jeevak Gupta, Managing Director of InvAscent, stated that the investment supports building a differentiated API business with long-term growth potential.

What the Numbers Show

The restructuring highlights a divergence between the internal transfer price and market valuation. While the slump sale consideration was ₹33.55 crore against a net worth of ₹70.92 crore, the initial ₹243.33 crore investment by ILSF and VJF implies a significantly higher valuation for the subsidiary. This structure leverages the spin-off to attract specialized capital for expansion, including the acquisition of key supply chain partners like Actis Generics.

Regulatory Disclosures

The disclosures were made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026. The transaction falls outside the Scheme of Arrangement and does not constitute the sale of substantially the whole undertaking under Section 180 of the Companies Act, 2013. Khaitan & Co. acted as legal counsel, o3 Capital as financial advisor, Quillon Partners as legal counsel for the acquisition, and Deloitte undertook financial due diligence.